{"gao_id": "GAO-20-301", "published": "2020-03-06T12:00:00Z", "released": "2020-04-06T08:00:00Z", "summary": "Before a drug can be marketed in the United States, the FDA must determine it is safe and effective. The company or entity seeking to market the drug must submit evidence for review. FDA\u2019s goal is to complete 90% of these reviews within deadlines that vary depending on the drug. Some drugs\u2014ones that may provide significant improvement over what\u2019s available\u2014receive priority designations for expedited reviews...", "title": "FDA Drug Approval: Application Review Times Largely Reflect FDA Goals", "topics": ["Drug safety", "Patient care", "Clinical trials", "Biologics", "Prescription drugs", "Authorizing legislation", "User fees", "Addiction", "New drugs", "Diseases", "Health Care", "Therapy", "Performance goals", "Dermatology", "Drugs"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-301", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-301-highlights.pdf"}, {"title": "Full Report (49 pages)", "url": "https://www.gao.gov/assets/gao-20-301.pdf"}, {"title": "Accessible PDF (55 pages)", "url": "https://www.gao.gov/assets/710/706384.pdf"}]}